News and Press Releases

In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. To date, this is one of the largest studies completed in Canada consisting of 360 patients with osteoarthritis (“OA”) of the knee, across 40 clinical sites.   

Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle

Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors
 Along the Pathway to Market Approval

Veristat Expands Operations into Taiwan to Support Growing Client Demand for Clinical Trial, Biostatistics and Programming Excellence in the Region

Opens office in Taipei, Taiwan

Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding

Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma

 Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That Reach Regulatory Approval

SOUTHBOROUGH, MA –  August 15, 2018 –   Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. 

SOUTHBOROUGH, MA –  May 30, 2017 –   Veristat, a full service Clinical Research Organization (CRO), congratulates TESARO, Inc. on the approval of ZEJULA™.  

Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts